RenovoRx(RNXT)
Focus: RenovoRx is a public medical device company specializing in catheter-based local drug delivery systems for oncology, particularly pancreatic cancer. The company is pre-revenue with minimal commercial traction and a highly experimental pipeline.
Profile data last refreshed 6h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
0
About RenovoRx
AI assessmentNot HiringNo open roles listed right now. Follow RenovoRx to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from RenovoRx's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Revenue
$43K
Pipeline & Clinical Trials
RenovoCath™ R120 Catheter
Pancreatic NeoplasmsClinical Trials (1)
NCT02591082Intra-Arterial Treatment of Pancreatic Cancer Using the RenovoCath™ RC120 Catheter
N/AHelp build intelligence for RenovoRx
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.